FDA revises EUA for Paxlovid to remove SARS-CoV-2 viral testing requirement

The FDA issued a fact sheet for healthcare providers on the Emergency Use Authorization for Pfizer’s Paxlovid, which indicates that the EUA has been revised to remove a previous requirement of SARS-CoV-2 viral testing. Reference Link